When acupuncture was combined with Metformin to treat
patients with type 2 diabetes mellitus, combined therapy induced significant
loss of body weight and improved insulin sensitivity compared with Metformin
alone. A randomized clinical study was reported in journal of Nutrition &
Diabetes.
Metformin
monotherapy is a first-line drug to type 2 diabetes mellitus, but its
effectiveness does not meet the expectation. Many patients with type 2 diabetes
mellitus were not satisfied with the outcome of treatment.
Recently a
group of clinical scientists led by Professor BM Zhu conducted a randomized
clinical study to assess the effect of combined acupuncture with Metformin on
type 2 diabetes mellitus compared with Metformin monotherapy. Thirty-nine
patients were divided into combined group and mono group. Patients in combined
group were given Metformin and acupuncture treatment. Electroacupuncture was
performed on 10 body acupoints plus some ear acupoints for 30 min each time, on
alternative day, 10 times within 3 weeks. Mono group were given Metformin only. Outcomes were measured by changes in serum inflammatory markers, lipid profiles
and adipokines at the baseline and end of 3-week treatment.
It was found
that acupuncture combined Metformin therapy significantly improved body weight,
body mass index, fasting blood sugar, fasting insulin compared with Metformin monotherapy
group. Further, combined therapy markedly reduced serum inflammatory markers,
lipid profiles and adipokines compared with monotherapy group.
The study
suggested that acupuncture combined Metformin therapy is more effective in
treating type 2 diabetes mellitus than Metformin monotherapy.
Reference
Firouzjaei A et al., Comparative evaluation of
the therapeutic effect of metformin monotherapy with metformin and acupuncture
combined therapy on weight loss and insulin sensitivity in diabetic patients. Nutr
Diabetes. 2016 May 2;6:e209. doi: 10.1038/nutd.2016.16. http://www.ncbi.nlm.nih.gov/pubmed/?term=Firouzjaei%20A%5BAuthor%5D&cauthor=true&cauthor_uid=27136447
No comments:
Post a Comment